Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Trials

2023-505268-12-00

EU Clinical Trials Information System

Trial ID
T-ctis-2023-505268-12-00
Registry
EU Clinical Trials Information System
CTIS number
2023-505268-12-00
Asset
COMP360
Sponsor, as registered
Compass Pathfinder Limited
Phase
Therapeutic confirmatory (Phase III)
Indication
Treatment-resistant depression
Status
Authorised
Start date
09/02/2024
Primary completion
CTIS does not publish one.
Member states concerned
Czechia, Denmark, France, Germany, Ireland, Netherlands, Poland, Spain, Sweden
Sites
36

Member states whose regulator has a decision on this trial.

euclinicaltrials.euctis registryverified 2026-08-31

Notes on the record

countries is memberStatesConcerned, i.e. every member state the trial is filed in; site_count sums trialSites across authorised Part II sections. primary_completion_date is EMPTY because CTIS does not publish a primary completion date; it is not unknown, it is not a field the registry has. Per-state authorisation is NOT recorded: mscPublicStatusCode takes values [5] on this record and the registry publishes no key for them, so decoding it would be a guess.

Company

Through COMP360: Compass Pathways

Cited in

Issues quoting 2023-505268-12-00 in their own text.